The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...

Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks ...

Overall, the majority of studies observe a significant association between genetic variants in DPYD and severe 5-FU-related toxicities. While this general finding seems to be reproducible across a ...

This enzyme, also known as DPD, is usually caused by inherited changes in a particular gene. Currently, there are internationally accepted dosing guidelines for 5-FU, adjusted according to DPD ...

Following conversion to 5-FU, 60–90% of capecitabine is catabolized by dihydropyrimidine dehydrogenase (DPD) ultimately to FBAL and 10–20% is excreted in urine unchanged. It has also been ...